Patent Foramen Ovale in Cryptogenic Stroke Study

Patent Foramen Ovale in Cryptogenic Stroke Study

The study sought to assess the rate of recurrent stroke and death in stroke patients with a patent foramen ovale randomized to treatment with warfarin or aspirin. This was a multicenter study conducted at 48 U.S. Institutions.

Inclusion Criteria:

• Age 30-85
• Ischemic stroke within 30 days
• Glasgow outcome scale ≥ 3
• No contraindications to warfarin/aspirin

Exclusion Criteria:

• Basal INR > 1.4
• Post-procedural stroke
• Severe carotid atherosclerosis
• Cardioembolic stroke
• Contraindications to transesophageal echocardiography